A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Effects of Pramlintide on Weight Reduction in Clozapine- and Olanzapine-Induced Weight Gain in Obese People Diagnosed With Schizophrenia.
Phase of Trial: Phase IV
Latest Information Update: 24 Nov 2018
At a glance
- Drugs Pramlintide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 21 Jun 2012 Actual patient number is 33 according to ClinicalTrials.gov.
- 21 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.